Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients
NCT07159620Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Sep 2025
- Primary completion
- Sep 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax in Early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) and t-cell acute lymphoblastic leukemia (T-ALL), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Composite Complete Remission Rate up to 42 days. Started Sep 2025; status: recruiting.
02
Drugs
venetoclax
03
Conditions
Early T-cell precursor acute lymphoblastic leukemia (ETP-ALL)t-cell acute lymphoblastic leukemia (T-ALL)
Beyond the preview
Go deeper on NCT07159620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07159620.